MIRA
INFORM REPORT
|
Report Date : |
02.01.2007 |
IDENTIFICATION
DETAILS
|
Name : |
CELOGEN
PHARMA PRIVATE LIMITED |
|
|
|
|
Registered Office : |
A
502, Tirupati Arcade, Plot No. 7, Sector 21, Kharghar, Navi Mumbai 410210
|
|
|
|
|
Country : |
India |
|
|
|
|
Date of Incorporation : |
13.04.2005 |
|
|
|
|
Com. Reg. No.: |
11-152619 |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24230MH2005PTC152619 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
MUMG11818C |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AABCL1038M |
|
|
|
|
Legal Form : |
Private
Limited Liability Company |
|
|
|
|
Line of Business : |
Manufacturer
of Pharmaceutical Products. |
RATING & COMMENTS
|
MIRAs Rating : |
Ca |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of
interest and principal sums in default or expected to be in default upon
maturity |
Limited with full security |
|
Maximum Credit Limit : |
|
|
|
|
|
Status : |
New
Company |
|
|
|
|
Payment Behaviour : |
Unknown
|
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject
has no track of performance and finance. It can
be considered for any business dealings on safe and secured trade terms and
conditions, initially |
LOCATIONS
|
Registered Office : |
A
502, Tirupati Arcade, Plot No. 7, Sector 21, Kharghar, Navi Mumbai 410210
|
|
Website : |
|
|
|
|
|
Factory
1 : |
Shree
Nanddham, 411- B, Sector 11, CBD Belapur, Navi Mumbai 400614 |
|
Tel.
No.: |
91-22-56743201 |
|
Fax
No.: |
91-22-56743202 |
DIRECTORS
|
Name : |
Mr.
Rabi Narayan Nayak |
|
Designation : |
Director
|
|
Address : |
Plot
No. 404, Manorama Housing Society, Plot No. 63, Sector 11, Kharghar, Navi
Mumbai 410210 |
|
Date of Appointment : |
13.04.2005 |
|
|
|
|
Name : |
Mr.
Sanjay Velappan Nair |
|
Designation : |
Director
|
|
Address : |
A
502, Tirupati Arcade, Plot No. 7, Sector 21, Kharghar, Navi Mumbai 410210
|
|
Date of Appointment : |
13.04.2005 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer
of Pharmaceutical Products. |
|
|
|
|
Products : |
Analgesics, Anti-inflammatory, Agents
& Antipyretics (NSAIDS) Anti Fungal Drugs |
GENERAL
INFORMATION
|
Bankers : |
Bank of Baroda Big Splash, Sector 17, Shop No. 126/66,
Shivaji Circle, Vashi, Navi Mumbai 400705, Maharashtra, India |
|
|
|
|
Facilities : |
-- |
|
|
|
|
Banking Relations : |
Satisfactory
|
|
|
|
|
Associates/Subsidiaries : |
Nil |
CAPITAL STRUCTURE
Authorised
Capital :
|
No.
of Shares |
Type |
Value |
Amount |
|
50000 |
Equity
Shears |
Rs. 10/- Each |
Rs. 0.500 Millions |
Issued,
Subscribed & Paid-up Capital :
|
No.
of Shares |
Type |
Value |
Amount |
|
10000 |
Equity
Shears |
Rs. 10/- Each |
Rs. 0.100 Millions |
FINANCIAL DATA
[all figures are in Rupees
Millions]
Nil
LOCAL AGENCY
FURTHER INFORMATION
Business
To carry
on in India and aboard the business to manufacturer, produce, process,
compound, formulate, mix, concentrate, grade, freeze, distillate, boil,
sterilize, buy, sell, import, export, transport, store, dispose off, market,
supply and to act as exporter, agent, broker, adatias, representatives,
consultant, collaborator, stockist, liasioner, middleman, job worker, in all
types decriptions, specification strengths and application of pharmaceutical
and chemical product of medicament in all its branches such as allopathic, ayurvedic,
herbal, siddha, bio chemic, injections, vitamin and products and all kinds
medical and surgical equipment
Form 8 Particular for creation or
modification of charges
|
Corporation identity number or foreign company registrations number of the company |
U24230MH2005PTC152619 |
|
Name of the company |
CELOGEN PHARMA PRIVATE LIMITED |
|
Address |
Shree Nanddham, 411- B, Sector 11, CBD
Belapur, Navi Mumbai 400614 |
|
This Form is for |
Creation of charge |
|
Type of Charges |
Equitable mortgage or mortgage of property by depositing the title deeds |
|
Particular of the charge holder |
Bank of Baroda Big Splash, Sector 17, Shop No. 126/66, Shivaji Circle, Vashi, Navi Mumbai 400705, Maharashtra, India |
|
Nature or description of the instrument creating charge |
Hypothecation agreement |
|
Date of the instrument creating charge |
08.02.2006 |
|
Amount Secure by the charge |
Rs. 3.400 millions |
|
Brief of the principal terms and conditions and extent and operation of the charge |
Interest for Packing Credit 3.50% below BPLR i.e. 7.00% p.a. Interest for Term Loan 2.75% over BPLR i.e. 13.25% p.a. Term Loa Repayable 36 monthly instalments of Rs. 0.011 million + Interest Margin Money 25% packing credit & 20% on Term Loan |
|
Description of the property charge whether it is a charge on |
Immovable properties, plant and machinery, stock in trade, book debts, vehicles and others If others, specify Consumable, stores & spares |
As Per
Website Details
Guiding Principles at Celogen Pharma Private
Limited
They believe that the essence of Pharma Production lies in the manufacture of Quality Products and Timely deliveries," which in turn creates customer value and satisfaction. Since its inception this has been the guiding principle enabling the Company to satisfy all their customers worldwide. The Company is constantly exploring possibilities to consolidate its presence and deliver value to clients.
All members at Celogen Pharma are individually and collectively committed to deliver the best in Pharmaceutical products and services in order to satisfy every customers needs through constant innovation, dedication, and providing a healthy work environment for all, and adopting the best in International practices.
It is noteworthy to mention that their facilities conform to WHO_GMP Standards and other regulatory specifications of different governing bodies.
Vision:
Grow to be a global pharma player, through excellence in core areas of
manufacturing & development.
Mission:
To ensure better quality of life for people all over by providing medicines
& supplements of high standards, at affordable prices.
Philosophy:
The corporate philosophy at Celogen is serving customers with Qualitative,
Effective, and Well on Time deliveries of their products.
The stakeholders of the Company lay a great importance in the realization of the mentioned principles, thereby effecting a positive synergy to the entire Value Chain ultimately benefiting the customer
Company
Police
One of the core values of Celogen Pharma is that they conduct their business consistent with all applicable laws, and are honest in their dealings with customers, employees, partners, suppliers, and the community. Consistent with this value, Celogen is committed to establishing and maintaining an effective and comprehensive compliance programme in accordance with the relevant governmental bodies and their policies and it is the central component of its commitment to the highest standards of corporate conduct in all its dealings.
Celogen's Company Policy remains a living, breathing entity, constantly changing to meet the rising demands of the market and the business environment. Celogen continuously reviews and enhances its policies to bring to its business partners the fruits of continuous development, enhancement of productivity, with quality being the keyword.
These are all followed by a strict programme of adherance and compliance through:
1. Leadership and Structure
2. Written Standards
3. Education and Training
4. Internal Lines of Communication
5. Auditing and Monitoring
6. Responding to Potential violations/errors
7. Corrective Action Procedures
It is their commitment
to be honest and ethical in business dealings and corporate responsibility. The
policies, procedures, and programmatic elements outlined above represent a
program responsive to manufacturing and quality concerns, which is consistent
with the values of the Company.
Quality
CELOGEN PHARMA strives
to conduct its business with a total commitment to their Customers and their
requirements. They define quality as conformance to their Customer's needs,
both internal and external; and conformance to all quality requirements.
At Celogen, Quality is the prime motto. The systems and
procedures are well framed to monitor and control process at various stages, so
that the final product meets the required standards and specifications.
Their personnel involved are made aware of the Quality
requirements at each level.
Review and improvement of these systems and procedures at
various stages are done. SOPs are maintained and updated periodically and
systems are made in accordance with the Good Manufacturing Practice, to meet
international standards.
Manufacturing
Location
Celogen has entered
into lease / license agreements with three state of the art manufacturing sites
for production of its products. The manufacturing is done as per Formulations
of Celogen, that are of top quality and conforming to stringent international
standards.
It goes to show their commitment to quality that their own
personnel supervise their products being manufactured, to ensure online
control.
CMT REPORT [Corruption, Money
laundering & Terrorism]
The
Public Notice information has been collected from various sources including but
not limited to: The Courts, India Prisons Service, Interpol, etc.
1] INFORMATION
ON DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court
Declaration :
No records exist to suggest that subject is or was the subject of any
formal or informal allegations, prosecutions or other official proceeding for
making any prohibited payments or other improper payments to government
officials for engaging in prohibited transactions or with designated parties.
3] Asset
Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record
on Financial Crime :
Charges or conviction registered
against subject: None
5] Records
on Violation of Anti-Corruption Laws :
Charges or investigation registered
against subject: None
6] Records
on Intl Anti-Money Laundering Laws/Standards :
Charges or investigation registered
against subject: None
7] Criminal
Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation
with Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation
Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA
INFORM as part of its Due Diligence do provide comments on Corporate Governance
to identify management and governance. These factors often have been predictive
and in some cases have created vulnerabilities to credit deterioration.
Our
Governance Assessment focuses principally on the interactions between a
companys management, its Board of Directors, Shareholders and other financial
stakeholders.
CONTRAVENTION
Subject
is not known to have contravened any existing local laws, regulations or
policies that prohibit, restrict or otherwise affect the terms and conditions
that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US
Dollar |
1 |
Rs.44.30 |
|
UK
Pound |
1 |
Rs.85.83 |
|
Euro |
1 |
Rs.57.92 |
SCORE &
RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
3 |
|
PAID-UP CAPITAL |
1~10 |
4 |
|
OPERATING SCALE |
1~10 |
- |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
- |
|
--PROFITABILIRY |
1~10 |
- |
|
--LIQUIDITY |
1~10 |
3 |
|
--LEVERAGE |
1~10 |
3 |
|
--RESERVES |
1~10 |
- |
|
--CREDIT LINES |
1~10 |
3 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
16 |
This score serves as a reference to assess SCs credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit
history (10%) Market
trend (10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial
base with the strongest capability for timely payment of interest and principal
sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No
caution needed for credit transaction. It has above average (strong)
capability for payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are
regarded healthy. General unfavourable factors will not cause fatal effect.
Satisfactory capability for payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors
carry similar weight in credit consideration. Capability to overcome
financial difficulties seems comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of
interest and principal sums in default or expected to be in default upon
maturity |
Limited with full security |
|
<10 |
C |
Absolute credit risk exists. Caution
needed to be exercised |
Credit not recommended |
|
NR |
In view of the lack of information, we
have no basis upon which to recommend credit dealings |
No Rating |
|